References
- Estey E, Thall P, Andreeff M, . Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994;4:671–678.
- Parker JE, Pagliuca A, Mijovic A, . Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997;99:939–944.
- Belizna CC, Kerleau JM, Heron F, . Vasculitis and myelodysplasia. Isr Med Assoc J 2008;10:156–157.
- Steurer M, Fritsche G, Tzankov A, . Large-vessel arteritis and myelodysplastic syndrome: report of two cases. Eur J Haematol 2004;73:128–133.
- Lopez FF, Vaidyan PB, Mega AE, . Aortitis as a manifestation of myelodysplastic syndrome. Postgrad Med J 2001;77:116–118.
- Olnes MJ, Sloand EM. Targeting immune dysregulation in myelodysplastic syndromes. JAMA 2011;305:814–819.
- Giannouli S, Voulgarelis M, Zintzaras E, . Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford) 2004;43:626–632.
- Giannouli S, Tzoanopoulos D, Ritis K, . Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression. Ann Rheum Dis 2004;63:578–582.
- Adiga GU, Elkadi D, Malik SK, . Abdominal aortitis after use of granulocyte colony-stimulating factor. Clin Drug Investig 2009;29: 821–825.
- Barrett AJ, Sloand E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica 2009;94:449–451.